Enodia Therapeutics announces research collaboration and license agreement with Pfizer to develop SEC61-targeting small molecules
PFE•Enodia Therapeutics and Pfizer agreed to collaborate on developing SEC61-targeting small molecules in a deal with potential value exceeding $500 million, including upfront payments, milestones and royalties.
1. Collaboration details
Enodia will conduct discovery activities to screen and optimize SEC61 inhibitor candidates against multiple collaboration targets. Pfizer will be responsible for clinical, manufacturing, regulatory and commercial activities.
